Introduction
The transforming growth factor-beta (TGF-b) signaling pathway is essential for cell polarity and lineage, and is a tumor suppressor pathway in multiple cell types (Souchelnytskyi et al., 2002; Tang et al., 2002; Siegel and Massague, 2003) . Smads are the intracellular mediators of TGF-b signals, and their regulation of Smad function is dependent on modulation by adaptor proteins such as SARA (Smad anchor for receptor activation), filamin, microtubules, and ELF (embryonic liver fodrin) (Roberts and Sporn, 1990; Heldin et al., 1997; Derynck and Zhang, 2003; Itoh et al., 2003) . Recently, disruption of the anchor function of ELF has been demonstrated to lead to tumorigenesis. Elf À/À -deficient mice have disrupted TGF-b signaling because of an alteration in ELF interactions with Smad3 and Smad4 (Tang et al., 2003b) . Smad4 is required for gut endoderm lineage, and Smad4 þ /À mice develop gastric tumors after 12 months . Smad2 plays a key role in gastrulation, while Smad3 is important for the establishment of the gastrointestinal mucosal immune response to TGF-b signals (Tang et al., 2003b) . Smad3-deficient mice frequently develop gut abscesses and die between 1 and 10 months from impaired mucosal immunity (Yang et al., 1999) . Defective liver development with loss of gastrointestinal epithelial cell shape and polarity is also seen in elf À/À homozygotes, Smad2 þ /À and Smad3 þ /À double heterozygous mice. Strikingly, hepatocellular carcinoma (HCC) is seen in elf þ /À heterozygotes (Weinstein et al., 2001) . ELF therefore is one of the few adaptor proteins that acts as a tumor suppressor. The regulation of ELF abundance therefore is likely to be important in tumorigenesis. Although gene dosage is critically important in this family (as haploinsufficiency phenotypes result in aberrant gut, brain, liver hypoplasia, and gastrointestinal carcinoma) (Weinstein et al., 2000; Shi and Massague, 2003; Siegel and Massague, 2003; Tang et al., 2003b) , other mechanisms, such as targeted protein proteolysis, also play an important role in the regulation of protein levels (Xu and Attisano, 2000) .
Biological functions of many proteins are altered by their covalent attachment to polypeptide modifiers (Schwartz and Hochstrasser, 2003) . The best-known example of this type of modification is ubiquitination (Li et al., 2003) . Ubiquitin-dependent protein degradation is involved in the regulation of various cellular processes, including cell cycle progression, signal transduction, transcription, DNA repair, and protein quality control (Koepp et al., 1999; Laney and Hochstrasser, 1999; Hicke and Dunn, 2003) . Recent studies have revealed the ability of Smads to interact with multiple components of the 26S proteasome system before and after Smad activation (Izzi and Attisano, 2004) . Ubiquitin is an abundant 76-amino-acid polypeptide that can be covalently conjugated to specific proteins by the formation of an isopeptide bond between its carboxyl-terminus and the amino group of a lysine residue of the target protein (Wang, 2003; Janse et al., 2004) . The selectivity of ubiquitination is largely mediated by the recognition of substrates by E3; posttranslational modifications, such as phosphorylation of the substrate, can regulate this interaction. To date, a number of RING E3 ligases have been characterized on a molecular level (Chen et al., 2005; Dupont et al., 2005; Zhong et al., 2005) . E3s with known amino-acid sequences include the N-end rule E3s of yeast and mammals and members of the HECT (homologous to E6-AP C-terminus) family (Dinudom et al., 1998) . Mammalian HECT E3s include E6-AP, which targets p53 for ubiquitination in the presence of human papillomavirus E6 (Honda and Yasuda, 1999) , and Nedd4, which ubiquitinates epithelial sodium channel subunits (Zhu et al., 1999; Liu et al., 2000) . Other E3s include Mdm2, which catalyses both its own ubiquitination and that of p53 (Koepp et al., 1999; Bonni et al., 2001) ; the anaphase-promoting complex (APC); and other F box and cullin-containing complexes whose substrates include Sic1p, G 1 cyclins, inhibitor of nuclear factor kB (IkB), and b-catenin (Laney and Hochstrasser, 1999) .
Interactions involving ubiquitination are an integral part of the signaling functions of Smads and other proteins and include several ubiquitin pathways. For instance Smurf2 an E3 ubiquitin ligase, regulates both cytoplasmic receptor-regulated Smads (R-Smad; such as Smad1) and nuclear R-Smad (such as Smad2 and Smad3) ubiquitination and proteasomal degradation (Kavsak et al., 2000; Stroschein et al., 2001) . Secondly, nuclear R-Smads (e.g. Smad3) show a novel ability to regulate the ubiquitination of several key regulators, such as the oncoprotein SnoN and the multidomain docking protein HEF1 (human enhancer of filamentation 1), through a physical interaction with different ubiquitin E3 ligases (HECT family, Skp1/cullin/F-box protein (SCF) family, and APC complex ). Nuclear R-Smads are ubiquitinated by the action of the SCF Fbw1a /Roc1 RING-H2 E3 ligase complex, which is exported to the cytoplasm and finally degraded there . Thirdly, TGF-b induces Smad7-Smurf1 association that export to the cytoplasm, and target the receptor kinases, which then undergo degradation Asano et al., 2004) . The Smurfs can also regulate ubiquitination and degradation of other target proteins, including the TGFb receptor complex and the transcriptional corepressor SnoN Fukuchi et al., 2001; Miyazono et al., 2003; Asano et al., 2004) .
These recently described physical links between Smads and E3 ligases of the 26S proteasome-ubiquitin system allow intracellular events triggered by the TGF-b family ligands to connect with those induced by many other extracellular regulators to form an extremely complex signaling network that regulates a wide range of biological activities (Izzi and Attisano, 2004) . Proteasomal degradation of Smad4 occurs in tumor cells, which either harbor deleterious mutations in MADH4 or express activated oncoproteins such as Ras (Xu and Attisano, 2000) . The ultimate degradation of nuclear Smads after prolonged ligand stimulation has been firmly established as a mechanism that shuts off the signaling pathway, yet the specific ubiquitination mechanism remains elusive.
More recently, PRAJA has been identified as a similar RING finger protein with E3 ligase activity in bone morphogenetic protein (BMP) pathway ubiquitination (Sasaki et al., 2002) . Praja open-reading frame (ORF) comprises 1188 bases encoding a 395-amino-acid protein of B60 kDa, and is involved in cell proliferation, apoptosis, juxtaposition, and architecture (also in Sanskrit: birth, development, and offspring) (Mishra et al., 1997) . PRAJA ORF exhibits extensive homology to RING finger proteins at the C-terminus end between residues 347 and 373 (Mishra et al., 1997) . Computer analysis of this domain demonstrates that it contains a perfect C 3 H 2 C 3 Zn-binding motif or RING-H2 finger found in many regulatory proteins, as well as several human proto-oncogene products such as promyelocytic leukemia protein (PML), ret finger protein (RFP), BRCA1, and inhibitors of apoptosis (IAP) (Schwede et al., 2003) . In this study, we show that expression of PRAJA is inversely related to that of ELF. PRAJA ubiquitinates ELF and Smad3, but not Smad4, in a TGF-b dependent manner. Here, we demonstrate that PRAJA E3 ligase activity regulates TGF-b signaling by controlling ELF abundance through ubiquitin-mediated degradation.
Results

ELF expression in liver tissue and regeneration
In order to demonstrate ELF expression during liver regeneration, we performed immunohistochemical staining on sections from livers after 70% partial hepatectomy (PH) at time points 0, 5, and 15 min, and 1, 3, 6, 12, 48 , and 72 h. Maximal staining for ELF was seen throughout the lobule at 0-5 min, and 6 h after PH, but diminished to almost undetectable levels at 1 and 48 h after PH (Figure 1a ), remaining only in centrilobular hepatocytes (Supplementary Figure 1b) . For these studies, we utilized a ELF-specific polyclonal antibody (VA-1) (Mishra et al., 1998 (Mishra et al., , 1999 Tang et al., 2002) that recognizes N-terminal sequence unique for ELF spectrin. Confocal experiments have shown ELF expression at the apical, canalicular surface of hepatocytes (Weinstein et al., 2001) . TGF-b levels during PH have been described before. Normal quiescent livers contain low level of TGF-b expression. During liver regeneration, at 4 h after PH, TGF-b expression rises threefold above normal levels, peaking to an eightfold level at the end of the 72 h post-PH (Braun et al., 1988; Russell et al., 1988) . A representative diagram has been presented in Figure 1b .
PRAJA is expressed at distinct time points in liver regeneration We further investigated expression of PRAJA during liver regeneration after PH and determined for correlation with ELF expression. We performed immunohistochemical staining, using polyclonal antibody specific for PRAJA (Mishra et al., 1997) , on sections from livers after 70% PH at time points 0, 5, and 15 min, and 1, 3, 6, 12, 48, and 72 h. PRAJA labeling was detectable in adult centrilobular hepatocytes, but not in Kupffer cells or hepatic stellate cells. During liver regeneration, PRAJA expression was induced in a distinctly time-dependent manner. Maximum labeling for PRAJA was observed throughout the lobule around 15 min after PH, before diminishing to almost undetectable levels at 6 h and then rising again after 48-72 h (Figure 1a ), remaining only in centrilobular hepatocytes. Thus, expression of PRAJA and ELF were inversely proportional to each other. We demonstrate here that during 4-6 h of the PH, peak expression of PRAJA occurs while TGF-b expression is already high (Figure 1a ) compared to expression in normal quiescent liver. Low ELF expression during that time frame reflects ELF ubiquitination and destruction by high expression of PRAJA in the presence of high levels of TGF-b, supported by the subsequent experiments. Cancer cell lysates show overexpression of PRAJA Loss of ELF is crucial for tumorigenesis, as is observed in our studies in hepatocellular, gastric, and colon cancers (Tang et al., 2005) . We demonstrate in this manuscript that ubiquitination of ELF by RING-H2 finger, PRAJA plays a critical role in its degradation via the proteasomal pathway. To test for overexpression of PRAJA in cancer cells, we chose two gastric cancer cell lines (NCI-N87) and (SNU-1) that show loss of ELF. Both cell lines showed a fivefold increase in PRAJA expression when compared to the normal gastric cells (Figure 1c ). The loss of ELF paired with the overexpression of PRAJA provides further support for an important role for PRAJA in ELF ubiquitination.
Stable cell lines expressing full-length PRAJA demonstrate loss of ELF To further demonstrate the reciprocal behavior of both ELF and PRAJA, we constructed two expression plasmids, one containing full-length PRAJA tagged with a small peptide V5 at C-terminus, and the other containing a deletion mutation of PRAJA, termed D-PRAJA in the same expression plasmid (in which the RING-H2 finger domain at the C-terminus has been deleted). A schematic representation of the constructs is shown in Figure 1d . Using these recombinant plasmids, we have generated two stable cell lines in HepG2 cells that constitutively express both V5-PRAJA and V5-D-PRAJA ( Figure 1e ). Deletion of RING-H2 domain results in the loss of ubiquitination, which is reflected on the rise in ELF expression levels. ELF is downregulated in cell lines that overexpress PRAJA, suggesting an interaction between the two. Conversely, ELF is upregulated and accumulates in the D-PRAJA-overexpressing stable cell line when compared to ELF levels in HepG2 cells. These studies indicate that interactions between ELF and PRAJA occur via RING finger domain, supporting a functional role in the differential expression of PRAJA and ELF, as was initially observed during PH. Increasing the concentration of ELF does not improve this interaction. This demonstrates that the association of ELF and PRAJA in a cell-free system can be saturated.
To determine whether PRAJA associates endogenously to ELF in the presence of TGF-b, we performed a protein-protein interaction assay using HepG2 cell lysates. TGF-b treatment was performed before harvesting the cells at indicated time points, with subsequent immunoprecipitation (IP) of PRAJA. As shown in Figure 2b , PRAJA co-immunoprecipitates with ELF at 30-60 min after TGF-b treatment, suggesting a role for PRAJA in ELF localization. The same association was observed when ELF antibody was used in IP and blotted with PRAJA antibody (Figure 2b ). Subcellular distributions of ELF and PRAJA were examined upon their expression in HepG2 cells by confocal microscopy ( Figure 2c ). We observed that both ELF and PRAJA were distributed diffusely across the cytoplasm and the cell membrane of the cells (Figure 2c ; I and IV subsequently), with weak colocalization signals (as shown in Figure 2c ; VII). Upon TGF-b stimulation, PRAJA label appears distinctly at the cell membrane at 30 min and 1 h later, especially at cell-cell contact sites 
PRAJA mediates ubiquitination of ELF and itself in the presence of TGF-b
The finding that ELF associates with the RING finger protein PRAJA prompted us to hypothesize that ELF may be a candidate substrate for PRAJA. We examined PRAJA E3 ubiquitin ligase activity for ELF in vivo.
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We also tested the TGF-b components Smad3 and Smad4 to determine whether they were also ubiquitinated by PRAJA. HepG2 cells were transfected with expression vectors encoding PRAJA, ELF, and HA-tagged ubiquitin. Cells were harvested following 30 mins treatment of TGF-b and the lysates were collected after 18 h. Ubiquitinated polypeptides were immunoprecipitated with ELF antibody and analysed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Western blot using an antibody to HA was performed to detect HAubiquitin-conjugated proteins. Ubiquitinated products were recognized by higher-molecular-mass products with a smear above the 200 kDa band representing ELF (Figure 3a , lane 1). In similar assays with Smad3 and Smad4, PRAJA did not generate ubiquitinated Smad4 products (Figure 3a , lane 5), although ubiquitinated Smad3 conjugates were observed (Figure 3a , lane 4). As RING finger subunits are essential components with E3 ubiquitin ligase activity and because these RING proteins recruit and activate E2s, we tested whether PRAJA might be an E3 ligase for itself and act as both E2 and E3. The products of substrateindependent ubiquitination reactions with PRAJA were analysed as above. Ubiquitinated conjugates of PRAJA were observed as a smear on top of wild-type PRAJA ( Figure 3a , lane 3).
RING finger mutations abolish E3 activity of PRAJA RING finger domains are conserved cysteine-rich amino-acid sequences that form two interleaved Znbinding sites. There are a total of eight cysteines and histidines that constitute the sites of metal coordination.
Computer analysis of this domain shows that it contains a perfect C 3 H 2 C 3 Zn-binding motif or RING finger found in many regulatory proteins, such as EL5 DNAbinding protein, as well as several human protooncogenes, such as Cbl, PML, RFP, and BRCAI and IAP ( Figure 5b ). RING-H2 fingers are classified based on the presence of a histidine in the fifth coordination site. The RING finger motif of PRAJA is suggested to be the recognition module for E2 and therefore necessary for E3 activity. Thus, we examined the effect of the mutant form of PRAJA, without the RING consensus, to determine for the abrogation of PRAJA induced ubiquitination of ELF in vivo and in the presence of TGF-b. A mutant form of PRAJA (D-PRAJA) was generated with deletion of the RING finger motif (Figure 1d ), resulting in the loss of E3 activity. Cotransfection in HepG2 cells with expression vectors tagged with D-PRAJA (mutant), ELF, and HAubiquitin do not ubiquitinate ELF in a dominantnegative mode. These results indicate that ELF is ubiquitinated in mammalian cells and that PRAJA is involved in its ubiquitination process via its RING finger ( Figure 3a , lane 2).
Dose-dependent ubiquitination of ELF by PRAJA
To test the possibility that ubiquitination of ELF by PRAJA is influenced by the enzyme-substrate ratio, we performed similar in vivo ubiquitination assays as described above, with increasing doses of PRAJA in the presence of a constant quantity of the substrate, ELF and TGF-b (100 pM final concentration). Low levels of ubiquitination of ELF were observed with low levels of PRAJA: ELF ratios (3Â :1Â), whereas slower migrating, higher levels of ubiquitinated forms of ELF were observed with higher levels of PRAJA:ELF ratios (6Â :1Â and 8Â :1Â) (Figure 3b ). This finding reveals that an efficient ubiquitination reaction can occur between ELF and PRAJA in cells with high levels of PRAJA.
Treatment with proteasomal inhibitors MG132 and MG115 leads to ELF accumulation
To test whether ubiquitinated ELF is targeted by the 26S proteasome, we conducted a time-point study in which HepG2 cells treated with MG132 and MG115 (data not shown) were harvested at 0, 2, 4, and 8 h.
Western blot analysis with an antibody to ELF revealed an accumulation of ELF at 6-8 h (Figure 3c ). Actin was used as a loading control. These results suggest that ELF is ubiquitinated by PRAJA and is marked for degradation by the proteasomal pathway. . Degradation of ELF is highly regulated by PRAJA in a TGF-b-dependent manner. This again strengthens our conclusion that ELF and PRAJA interact with each other and that PRAJA acts as an E3 ubiquitin ligase and ubiquitinates ELF, initially modifies ELF and subsequently destroys it.
Discussion
Inhibition of the antiproliferative effect of TGF-b is often associated with progression of tumorigenesis in human cancers (Markowitz and Roberts, 1996) . Here, we demonstrate strong evidence that the RING finger (RING-H2) protein PRAJA ubiquitinates ELF, a tumor suppressor and a Smad adaptor protein that is involved in TGF-b signaling, and that PRAJA may play an important regulatory role in liver regeneration. A model representing PRAJA as a potential regulatory protein in TGF-b signaling pathway is shown in Figure 5a . In brief, we propose that, upon TGF-b induction, TGF-b serine/threonine kinase receptor II activates TGF-b receptor I. This is followed by ELF phosphorylation and subsequently a complex is formed between ELF and Smad3 that is in turn phosphorylated by the type I receptor. Thereafter, PRAJA emerges as an E3 ubiquitin ligase that attaches ubiquitin molecules to ELF and localizes the complex towards the plasma membrane. At the same time, ubiquitin chains elongate and ELF is displaced from the signaling pathway and then becoming a target for 26S proteasome and is destroyed. Under normal circumstances, Smad4, Smad3, and phosphorylated ELF form a complex that maintains the signaling pathway for the normal growth of the cells. Indeed, disruption of TGF-b signaling is seen in almost all gastrointestinal cancers. A ribbon and stick model of the best-fit superposition of the RING-H2 domain of PRAJA, simulated by the Swiss-Prott model protein data bank (PDB) repository, is shown in Figure 5b . The hypothetical energy TGF-b signaling is modulated by ubiquitination of ELF by PRAJA T Saha et al minimum tertiary structure is designed from the structurally similar RING-H2 finger protein EL5 (PDB code: 1LYM). The backbone of this motif is shown in green and contains one a chain and two b-pleated sheets nearby (dashed square box). The protein is folded in such a way that it can accommodate two Zn molecules in the clefts shown by yellow arrows and this Zn and RING finger motif are both responsible for its function.
Studies using PH in mouse indicate that, in liver regeneration, PRAJA peaks at 15 min and 48-72 h by immunohistochemical labeling after PH. ELF induction occurs later, during liver regeneration, showing a peak at 6 h after PH with a concomitant decrease of PRAJA (6 h after PH). Similarly, at 48 and 72 h, PRAJA levels increase, with a concomitant decrease in ELF expression. Our findings suggest that PRAJA could be a key mediator of ELF degradation and that endogenous levels of ELF are dynamically regulated through a possible ELF-PRAJA feedback loop via the ubiquitinmediated proteasomal pathway. The differential activity of PRAJA, both as an essential regulatory protein in hepatocyte development and as an ubiquitinator of ELF, an important tumor suppressor adaptor protein, inhibits apoptosis, and is possibly dictated by its own intracellular concentration. Our hypothesis is that low levels of PRAJA maintained in normal gastrointestinal cells are likely to play important regulatory roles for normal development. However, when PRAJA activities are high, PRAJA-mediated ubiquitination induces ELF degradation, abrogating the ELF-Smad TGF-b signaling pathway, thereby leading to tumorigenesis (Figure 1) .
The results in this study demonstrate that the RING finger protein PRAJA is regulated by TGF-b; that it facilitates ubiquitination of ELF, a tumor suppressor adaptor protein involved in TGF-b signaling; and that it may play an important regulatory role in liver development. Results of the assays we utilized suggest that PRAJA may have differential effects in determining ELF fate. In gastrointestinal cell differentiation, biological signals for TGF-b are transduced through transmembrane serine/threonine kinase receptors that signal to Smad proteins (Roberts and Sporn, 1990; Heldin et al., 1997; Souchelnytskyi et al., 2002; Derynck and Zhang, 2003; Itoh et al., 2003; Siegel and Massague, 2003; Tang et al., 2003b) . Interactions involving ubiquitination are an integral part of the signaling functions of Smads, involving at least six ubiquitin pathways (Kretzschmar and Massague, 1998) . The common mediator, Smad4, a tumor suppressor, is often inactivated in human gastrointestinal cancers (Zhang et al., 1997) . However, the mechanism by which Smad4 mutations interfere with Smad activity remains uncertain. Our previous studies have shown that disruption of ELF, a Smad4 adaptor protein, inactivates TGF-b signaling, with elf þ /À mutant mice that develop HCCs. Conforming to these observations, the present study indicates that PRAJA, a RING finger E3 ubiquitin ligase, interacts with ELF and ubiquitinates it. ELF associates with PRAJA in a TGF-b-dependent manner. ) A ribbon model of the best-fit superposition of the RING finger (RING-H2) (C 3 H 2 C 3 ) domain of PRAJA, simulated by the SwissPrott model PDB repository. The hypothetical tertiary structure was designed from the structurally similar RING finger protein EL5 (PDB code: 1LYM). This structure contains one a helix and two b-pleated sheets that remain in the white box shown in the figure. It also accommodates two zinc molecules in the clefts that were indicated by yellow arrows. Table 1 Determination of t 1/2 (half-life of ELF) and k D (rate constant of the degradation of ELF) in our experimental samples TGF-b signaling is modulated by ubiquitination of ELF by PRAJA T Saha et al
After 30 min of TGF-b induction, a strong interaction is observed (Figure 2b and c) , which is approximately when the ELF-Smad heteromeric complex translocates into the nucleus. These studies raise possibilities that PRAJA interaction and degradation of ELF could result in the disruption of Smad4 signaling, with a potential role in the development of HCCs. Indeed, we have found a fivefold increase in PRAJA expression with a concomitant decrease in ELF and Smad4 expression in gastrointestinal cancers (Po0.05) (Figure 1c) . It is interesting to note that escape from TGF-b growth inhibition occurs in the presence of PRAJA (60% more growth), as well as, to a lesser extent, with D-PRAJA, suggesting a dominant-negative role for D-PRAJA. These results are similar to those for Cbl, where substrate recognition and association are independent of activation (Joazeiro et al., 1999) . Treatment with potent proteasomal inhibitors MG132 result in the accumulation of ELF at the end of 8 h, indicating that PRAJA ubiquitinates ELF and that its degradation is mediated via the proteasomal pathway (Figure 3) . The functional role of ubiquitinated ELF and the possible role of RING-mediated ubiquitination await further study. One possibility is that RING finger protein PRAJA ubiquitinates ELF (Figure 3 ) and therefore provides it with an important cellular function, which is further supported by the ELF-PRAJA interactions modulated by TGF-b (Figure 2 ). These observations are analogous to studies on other oncogenic E3 ligases, such as Mdm2 and its substrate, p53 (Li et al., 2003) .
RING E3s, which mediate ubiquitination, represent the largest E3 family known to date and include the c-Cbl proto-oncogene product, the multisubunit SCF and APC cell cycle-regulatory complexes, the Mdm2 protooncogene product that regulates the p53 tumor suppressor, BRCA1, and members of the IAP family of antiapoptotic proteins (Sun, 2003) . In addition, it is possible that, in vivo, changes in conformation, alterations induced by phosphorylation, and changes in intermolecular associations, such as dimerization, may influence the capacity of RING finger proteins to function with E2s in ubiquitination. Adhering to these attributes, the compact RING module of PRAJA could confer an additional regulatory role on a wide array of TGF-b signaling proteins that associate with it. Recent studies also show that PRAJA ubiquitinates Dlxin-1 and Msx2 proteins and thus regulates the transcriptional function of homeodomain protein DLX5 through Dlxin-1 via an ubiquitin-dependent degradation pathway (Sasaki et al., 2002) . Importantly, this observation confirms the role of PRAJA in the TGF-b/BMP pathway.
The importance of RING finger domain in ubiquitination is further supported by the fact that in vivo assays with the RING finger mutant PRAJA (D-PRAJA) abolish ubiquitination of ELF (Figure 3) . RING mutations of BRCA1 are associated with familial carcinomas. Strikingly, PRAJA manifests substantial E3-dependent ubiquitination of ELF, but not Smad4, while still exhibiting ubiquitinated Smad3 conjugates. This finding suggests a role for PRAJA in the membrane localization of the ELF and the Smad signaling complex. Furthermore, it is observed that in the absence of a substrate, PRAJA has the capacity to ubiquitinate itself. This ability is consistent with recent observations that multiple, otherwise unrelated RING finger proteins, including Mdm2, AO7, Siah1, kf-1, have the inherent capacity to ubiquitinate themselves (Lorick et al., 1999) .
RING mutations of BRCA1 are associated with familial carcinomas (Brzovic et al., 1998) . A potential model for RING-mediated E3 activity is one in which the RING and surrounding regions not only associate with E2-ubiquitin but also provide a favorable environment for the transfer of ubiquitin from E2 to an available lysine. Such a mechanism is analogous to the mechanism in models for the function of N-end rule E3s (Ohta et al., 1999) . RING proteins, defined by eight cysteines and histidines that coordinate two zinc ions, vary substantially in length and composition. RINGs have cysteines in the first three and last three coordination sites and a His in the fourth site. Additionally, proteins bearing this motif have either a Cys [C 3 HC 4 RING (RING-HC)] or a His [C 3 H 2 C 3 RING (RING-H2)] in the fifth position. The first, second, fifth, and sixth cysteines/histidines coordinate one cation, and the third, fourth, seventh, and eighth coordinate the second (Saurin et al., 1996) . As determined with consensus sequences, PRAJA falls into the RING-H2 category, with the amino acids indicated predicted to be coordination sites.
Here, we establish such a mechanism by showing that pathway and growth of cells that are dependent on an adaptor protein ELF is inactivated by PRAJA, an E3 ligase. Multiple other cancers derived from mesoendodermally derived epithelium are associated with TGF-b/ BMP pathway inactivation, where it may regulate progenitor cell fate (Souchelnytskyi et al., 2002; Siegel and Massague, 2003; Tang et al., 2003a) . Indeed, the functions of TGF-b are complex and extend beyond their role in the inhibition of cell growth. TGF-b induces the growth of mesenchymal cells, alters synthesis of extracellular matrix components, and metalloproteases, which is involved in cell invasion (Roberts and Sporn, 1990; Heldin et al., 1997; Souchelnytskyi et al., 2002; Derynck and Zhang, 2003; Itoh et al., 2003; Tang et al., 2003b) . TGF-b signals also modulate the immune response to tumors and are thought to play a role in tumor angiogenesis (Wieser, 2001) . The development of gastrointestinal tumors in elf
mutants indicates a crucial role for ELF, a b-spectrin, which acts as an essential adaptor protein for the proper transmission of signals generated by the TGF-b pathway. These studies demonstrate that loss of expression of ELF through PRAJA could play an important role in the development of gastrointestinal tumors, which are among the most lethal forms of cancers.
Materials and methods
Animals and PH
PH was carried out, as described before (Bhanumathy et al., 2002) , on Harlan mice. Briefly, a median incision line was TGF-b signaling is modulated by ubiquitination of ELF by PRAJA T Saha et al made, exposing the large median lobe and the left lateral lobe. The hepatic duct was ligated and both lobes were excised. Thus, hepatic parenchyma constituting 65-75% was removed, leaving the right lateral lobe and the small caudate within the peritoneum. Following PH, the animals were killed at different time points of 0, 5, and 15 min, and 1, 3, 6, 12, 48, and 72 h. Subsequently, the liver residual mass was excised at different time points of 0, 5, and 15 min, and 1, 3, 6, 12, 48 , and 72 h, and fixed in 4% paraformaldehyde for paraffin section. The slides from the paraffin section were stained with the respective antibodies as indicated and quantitated by using the DP70 software (Olympus) in a PC computer directly attached to the microscope (Olympus).
Construction of the plasmids and stable cell lines cDNA sequence of PRAJA was amplified by gene-specific primer and inserted into either pcDNA3.1/V5-His-TOPO (V5-PRAJA) or pCMV mammalian expression vectors (pCMV-PRAJA) (Invitrogen). cDNA sequences corresponding to the RING-H2 domain (347-391 amino acids) of wild-type PRAJA were deleted by site-specific polymerase chain reaction to construct V5-D-PRAJA or pCMV-D-PRAJA, and then subsequently subcloned into the same mammalian expression vector. These recombinant plasmids were used in transfection studies. For the generation of the stable cell lines, PRAJA and D-PRAJA mammalian expression plasmids were transfected into HepG2 cells and the stable integrants were selected using 600 mg/ml Geneticin (Invitrogen).
Cell culture and treatments
The human HCC cell line, HepG2 (American Type Culture Collection (ATCC) #HB-8065), along with stable cell variants expressing V5-PRAJA and V5-D-PRAJA, were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ ml penicillin, and 100 mg/ml streptomycin in 5% CO 2 . Human gastric cancer cell lines NCI-N87 (ATCC #CRL-5822) and SNU-1 (ATCC #CRL-5971) were maintained in the RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, and antibiotics in 5% CO 2 (all media and reagents were purchased from GIBCO, Invitrogen). TGF-b (Sigma) was added to a final concentration of 100 pM and cultures were incubated for 15, 30, and 60 min.
Transfection and thymidine incorporation assays
Cells were seeded at a density of 2 Â 10 5 cells/well in six-well dishes and were then transfected using either ELF or PRAJA expression constructs, or the vector alone (3 mg of DNA/well), using Fugene 6 as a transfection reagent (Roche). Following transfections, cells were washed with 2 Â DMEM after 12-18 h and then treated with 5 mg/ml of TGF-b before being incubated for an additional 24 h. The cells were pulsed with [ 3 H]thymidine for the final 2 h of the treatment period. Cells were then collected by trypsinization and put on a filter paper for the quantification of [ 3 H]thymidine incorporation, using an LS 6500 Multi-purpose Scintillation Counter (Beckman). All experiments were repeated at least three times, and similar results were obtained each time.
Immunohistochemistry
An indirect immunoperoxidase procedure was used for immunohistochemical localization of ELF and PRAJA protein in regenerating mouse liver. An antibody to a peptide corresponding to amino acids 145-159 (CLRRKYRS-REQPQS) specific for PRAJA was produced in rabbit as described previously and used to detect PRAJA by immunohistochemical labeling (Mishra et al., 1997) . For ELF, the primary antibody was rabbit anti-mouse VA-1 (against Nterminal amino acids 2-14, ELQRTSSVSGPLS, specific for ELF) described previously (Mishra et al., 1998 (Mishra et al., , 1999 . Paraffin-embedded sections (8 mm) were deparaffinized in xylene and graded alcohol and rinsed in 1 Â phosphatebuffered saline (PBS). Endogenous peroxidase was quenched using 3% hydrogen peroxide (Sigma). Nonspecific binding sites were blocked in 1 Â PBS containing 5% goat serum and 1 mg/ml bovine serum albumin (BSA) for 1 h. The sections were incubated overnight at 41C in a humidified chamber with primary antibody diluted to 2.5-5 mg/ml in 1 Â PBS containing 1 mg/ml BSA and 0.05% Triton X-100. All further steps were performed at room temperature, including four, 5-min rinses with 1 Â PBS containing 1% goat serum after each successive step. Sections were incubated with peroxidase-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch Laboratories) that was diluted in PBS with 1% serum, for 30 min. After four rinses, 200-500 ml of the insoluble peroxidase substrate diaminobenzidine (Pierce) was added to cover the entire tissue on the slide for color development, prior to an additional 2 min rinse in distilled water. Counterstaining was then performed with Harris's hematoxylin solution (modified) (Sigma) for 1 min, followed by a rinse in distilled water for 5 min. Sections were dehydrated by passages through graded alcohol concentrations and finally with xylene. Coverslips were mounted using DPX (Fluka Labs) and monitored under a microscope.
In vitro interaction assay TNT-T7-coupled transcription/translation system from Promega was used to produce exogenous proteins from the constructed plasmid (Chatterjee-Kishore et al., 2000; Yin et al., 2002) . [ 35 S]methionine was used in the reaction mixture to make the proteins label and thus can be detected by autoradiography. The produced proteins were then immunoprecipitated from the reaction mixture, as described below, by respective antibodies and used in our interaction assay. The binding assay was performed in 50 mM Tris, pH 7.4, 2 mM ATP, and 5 mM MgCl 2 , before being incubated at 371C for an hour. Following incubation, it was again immunoprecipitated and resuspended in SDS lysis buffer. The samples were separated in 4-12% NuPage Bis-Tris gel (Invitrogen). The gel was then dried and autoradiographed after 4 days.
Co-IP and immunoblot
To analyse ELF-PRAJA interactions under the influence of TGF-b, HepG2 cells were treated with 100 pmol/ml final concentration of TGF-b. Cells were harvested at different time points of 0, 15, 30, and 60 min, and were lysed in 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholic acid, 50 mM Tris buffer pH 7.5, containing 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 10 mg/ml leupeptin. For IP, lysed cells were incubated with respective antibodies as indicated in the figures for 2 h at 41C and then incubated with protein G plus agarose beads (Amersham) overnight at 41C. Individual host serum was used in the same way that serves the negative control in IP. Immunocomplexes were washed with detergent-PBS and were fractionated on SDS-PAGE (6% or 4-12% gel; Novex) and blotted to nitrocellulose membrane. Western blotting (WB) was performed as before (Mishra et al., 1998; Mishra et al., 1999) . Enhanced chemiluminescence (ECL) kit (Perkin-Elmer Life Sciences) was used to develop the immunoblots. The loading control was performed under the same conditions using actin specific antibody (Santa Cruz Biotechnology Inc.).
Confocal laser scanning immunofluorescence microscopy
Colocalization studies were performed with anti-ELF (polyclonal, VA-1), anti-PRAJA (polyclonal) antibody on mouse embryonic fibroblasts. Primary antibodies were visualized with either tetramethyl rhodamine isothiocyanate-conjugated goat anti-rabbit immunoglobulin G; fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin G, or cyanine (Cy5) (all secondary antibodies from Jackson ImmunoResearch Laboratories). The samples were analysed on a Bio-Rad MRC-600 confocal microscope (Bio-Rad), with an ILT model 5470 K laser (Ion Laser Technology) as the source for the crypton-argon ion laser beam. FITC-stained samples were imaged by excitation at 488 nm and Rhodamine-stained samples were imaged by excitation at 568 nm with a 598-621 bandpass emission filter with a 505-540 bandpass emission filter. Cy5-stained samples were imaged by excitation at 638 nm with a 647-670 bandpass emission filter using a Â 60 (numerical aperture 1.3) objective and Â 20 objective. Digital images were analysed using Metamorph software (Universal Imaging). Figures were prepared using Adobe Photoshop.
In vivo ubiquitination assays
To detect ubiquitinated forms of ELF, HepG2 cells were transfected/cotransfected with expression vectors encoding ELF, PRAJA, Smad, and HA-tagged ubiquitin individually as well as in combination. At 24 h post-transfection, cells were treated for 3 h with a potent 26S proteasome inhibitor MG132 (10 mM final concentration; Calbiochem) and 30 min with TGF-b (100 pM final concentration) before harvest, and were lysed in RIPA buffer (100 mM NaCl, 1.0% NP-40, 0.5% deoxycholate, and 50 mM Tris (pH 8.0)) for 30 min at 41C. Following incubation, the lysates were collected as a supernatant after centrifugation at maximum speed at 41C temperature. Samples were analysed by Western blot with a protein-specific antibody. ELF was immunoprecipitated using VA-1 (ELF specific antibody) and was subjected to SDS-PAGE. Ubiquitinated ELF conjugates were detected by WB using antibodies against hemagglutinin (HA) (12CA5; Boehringer Mannheim, Mannheim, Germany). Similar assays were performed to detect ubiquitinated conjugates of Smad3 and Smad4 with antibodies specific for Smad3 and Smad4 (Santa Cruz Biotechnology Inc.).
Cycloheximide treatment of cells for determination of half-life of ELF HepG2 cells were seeded at 2 Â 10 6 cells/ml in culture medium in six-well tissue culture dishes the day before the experiment. Transfection with PRAJA and D-PRAJA was performed as above. Where indicated, 24 h following transfection, 75 mg/ml final concentration of cycloheximide solution in DMSO (Sigma) was added to the cells and maintained at indicated time points (1-4 h) (Pan and Haines, 1999; Alarcon-Vargas et al., 2002) . Cells were treated with TGF-b for 30 min prior to harvesting at different time points after cycloheximide treatment and washed with PBS before lysates were prepared in SDS cell lysis buffer. The samples were fractionated in 4-12% NuPage Bis-Tris gel (Invitrogen). Decay curves were prepared using the band intensity of both ELF and actin at different time points and the equation was generated using the Cricket Graphics program in Macintosh.
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